PSTX Logo

Poseida Therapeutics, Inc. (PSTX) 

NASDAQ
Market Cap
$264.73M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
677 of 774
Rank in Industry
366 of 432

Largest Insider Buys in Sector

PSTX Stock Price History Chart

PSTX Stock Performance

About Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating …

Insider Activity of Poseida Therapeutics, Inc.

Over the last 12 months, insiders at Poseida Therapeutics, Inc. have bought $0 and sold $0 worth of Poseida Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Poseida Therapeutics, Inc. have bought $6.75M and sold $7.05M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 2,150,000 shares for transaction amount of $7.53M was made by Malin Life Sciences Holdings Ltd () on 2022‑08‑08.

List of Insider Buy and Sell Transactions, Poseida Therapeutics, Inc.

2022-08-08Purchase
2.15M
2.6659%
$3.50$7.53M+0.14%
2022-08-08PurchaseExecutive Chairman
142,857
0.1771%
$3.50$500,000+0.14%
2022-08-03SaleExecutive Chairman
160,696
0.1723%
$3.69$592,808-17.29%
2022-03-16PurchaseChief Operating Officer
3,000
0.0048%
$3.98$11,940+3.27%
2021-12-06Purchase10 percent owner
1,828
0.003%
$6.90$12,613-43.32%
2021-12-02Purchase10 percent owner
4,296
0.0065%
$6.88$29,550-47.09%
2021-12-01Purchase10 percent owner
18,365
0.0295%
$6.85$125,806-44.07%
2021-11-30Purchase10 percent owner
28,592
0.0451%
$6.85$195,838-45.04%
2021-11-29Purchase10 percent owner
11,057
0.0177%
$6.89$76,209-44.56%
2021-11-26Purchase10 percent owner
27,251
0.0433%
$6.81$185,492-44.23%
2021-11-24Purchase10 percent owner
1,054
0.0016%
$6.89$7,260-46.80%
2021-11-23Purchase10 percent owner
14,625
0.0227%
$6.77$98,989-45.35%
2021-11-19Purchase10 percent owner
11,104
0.0174%
$7.44$82,650-49.74%
2021-11-18Purchase10 percent owner
71,312
0.1129%
$7.18$511,685-47.31%
2021-11-17Purchase10 percent owner
280,384
0.4549%
$7.21$2.02M-46.27%
2021-11-17PurchaseChief Operating Officer
2,000
0.0032%
$7.00$14,000-46.27%
2021-11-16Purchase10 percent owner
27,680
0.0441%
$7.17$198,383-46.87%
2021-11-08SaleChief Executive Officer
18,924
0.0324%
$7.09$134,171-42.30%
2021-10-01SaleChief Executive Officer
20,029
0.0319%
$7.02$140,604-43.97%
2021-09-20SaleChief Executive Officer
20,000
0.0322%
$8.00$160,020-47.62%

Insider Historical Profitability

<0.0001%
Malin Life Sciences Holdings Ltd
11835673
12.1435%
$2.72130<0.0001%
Hirsch Daviddirector
2714245
2.7848%
$2.7210<0.0001%
Ostertag EricExecutive Chairman
838824
0.8606%
$2.72122+0.14%
Ingalls Kerry D.Chief Operating Officer
55000
0.0564%
$2.7220<0.0001%
Lloyd Marcea Blanddirector
10000
0.0103%
$2.7210<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Fidelity Investments$46.17M14.9314.47M+0.9%+$413,755.76<0.01
Hudson Bay Capital Management LP$19.06M6.165.97M0%+$00.53
BlackRock$15.79M5.114.95M-1.61%-$258,718.57<0.0001
Boxer Capital, LLC$14.28M4.624.47MNew+$14.28M0.29
Silverarc Capital Management Llc$11.47M3.713.6M-2.95%-$348,676.560.12
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.